Clinical Trials Browser

Phase 3 × INDUSTRY × cabozantinib × Clear all

NCT07227402 2026-06-04

LITESPARK-033

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

NCT07011719 2026-06-02

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase 3 Recruiting

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Phase 3 Not yet recruiting

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT07405164 2026-05-29

MK-6482-043

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04586231 2026-05-05

MK-6482-011

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT03768063 2026-04-28

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT04211337 2026-03-19

LIBRETTO-531

Phase 3 Active not recruiting

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Carcinoma, Renal Cell

NCT04471428 2025-12-22

CONTACT-01

Phase 3 Completed

366 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Prostatic Neoplasms

NCT03755791 2025-12-11

COSMIC-312

Phase 3 Active not recruiting

837 enrolled 14 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT03690388 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Phase 3 Active not recruiting

187 enrolled 13 charts 1 FDA

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT03937219 2025-09-10

COSMIC-313

Phase 3 Active not recruiting

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT04760288 2024-01-05

AcceleRET-MTC

Phase 3 Withdrawn

Carcinoma, Medullary

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase 3 Terminated

623 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01908426 2021-05-06

CELESTIAL

Phase 3 Completed

707 enrolled 20 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01865747 2021-04-27

METEOR

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

NCT01522443 2018-05-23

COMET-2

Phase 3 Terminated

119 enrolled 21 charts

Pain, Prostatic Neoplasms

NCT01605227 2018-03-14

COMET-1

Phase 3 Completed

1,028 enrolled 18 charts

Pain, Prostatic Neoplasms